Loading...
XKRX
064550
Market cap282mUSD
Jul 29, Last price  
15,190.00KRW
1D
-1.81%
1Q
-3.62%
Jan 2017
106.11%
IPO
19.61%
Name

BioneerCorp

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
1.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.90%
Rev. gr., 5y
51.95%
Revenues
293.98b
+11.68%
20,533,917,88023,904,100,69017,853,516,18020,833,715,30721,703,614,69923,267,735,47424,077,825,95636,292,396,635206,987,464,643223,743,694,062218,394,453,243263,236,802,635293,975,485,090
Net income
-20.58b
L+94.43%
-8,022,353,080-7,152,484,830-13,559,179,820-5,372,140,420-14,418,909,089-9,941,285,943-8,818,353,336-7,826,653,51057,899,192,63027,159,523,57012,076,878,840-10,587,029,811-20,584,198,230
CFO
-13.48b
L
-2,714,095,840-3,787,214,090-4,314,334,030407,678,862-2,511,535,212-3,902,011,230-8,113,572,202-5,589,453,06295,705,376,69653,174,659,3108,805,263,1774,135,856,100-13,476,386,430
Dividend
Mar 15, 20220.285 KRW/sh

Profile

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.
URL
https://www.bioneer.co.kr/
IPO date
Dec 29, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
293,975,485
11.68%
263,236,803
20.53%
218,394,453
-2.39%
Cost of revenue
270,792,247
226,744,852
176,032,647
Unusual Expense (Income)
NOPBT
23,183,238
36,491,951
42,361,807
NOPBT Margin
7.89%
13.86%
19.40%
Operating Taxes
3,717,024
6,851,604
(1,217,551)
Tax Rate
16.03%
18.78%
NOPAT
19,466,213
29,640,347
43,579,357
Net income
(20,584,198)
94.43%
(10,587,030)
-187.66%
12,076,879
-55.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
46,278,858
30,282,504
19,645,139
Long-term debt
29,612,426
17,156,233
8,224,875
Deferred revenue
2,210,880
10
756,344
Other long-term liabilities
5,702,884
9,962,888
6,726,793
Net debt
28,921,090
(52,471,808)
(59,837,251)
Cash flow
Cash from operating activities
(13,476,386)
4,135,856
8,805,263
CAPEX
(12,634,861)
(5,491,491)
(18,523,655)
Cash from investing activities
(21,874,796)
(13,468,343)
(19,148,743)
Cash from financing activities
26,105,833
14,054,749
4,674,171
FCF
1,252,587
28,857,612
(8,529,407)
Balance
Cash
94,258,533
91,833,053
80,034,585
Long term investments
(47,288,339)
8,077,492
7,672,680
Excess cash
32,271,420
86,748,705
76,787,543
Stockholders' equity
(24,615,728)
26,156,006
34,818,809
Invested Capital
320,168,070
263,323,565
239,629,587
ROIC
6.67%
11.79%
18.86%
ROCE
7.41%
12.50%
15.21%
EV
Common stock shares outstanding
22,686
25,810
25,810
Price
18,850.00
-43.39%
33,300.00
13.27%
29,400.00
-39.51%
Market cap
427,625,219
-50.25%
859,482,690
13.27%
758,822,555
-38.29%
EV
469,519,467
818,011,713
706,522,644
EBITDA
32,311,058
45,444,779
49,621,003
EV/EBITDA
14.53
18.00
14.24
Interest
3,417,511
1,407,616
647,917
Interest/NOPBT
14.74%
3.86%
1.53%